GlassScriptPhysician profile
Joseph James Gallo
NPI 1376540195
$20,961.76
in general payments reported to CMS, 2019-2025
59 companies · $3,973 in 2025
The $3,973 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,365 · 2020: $2,040 · 2021: $3,462 · 2022: $2,845 · 2023: $3,083 · 2024: $3,193 · 2025: $3,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $39.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,210.21 |
| Education | $39.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,423.58 | 2021-2025 | |
| Novo Nordisk INC | $1,786.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,738.97 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,534.42 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Lilly USA, LLC | $1,428.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,292.14 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $1,226.13 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $748.76 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $692.33 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $682.96 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $641.92 | 2019-2025 | |
| Corcept Therapeutics | $592.53 | 2023-2025 | Korlym |
| Astellas Pharma US INC | $493.82 | 2020-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $464.34 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $456.35 | 2019-2023 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.